Polycystic Kidney, Autosomal Dominant - 25 Studies Found
Completed |
: Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease : Autosomal Dominant Polycystic Kidney Disease : 2007-12-31 : Drug: Tetracosactin 1 microgram tetracosactin, intravenous injection, once for the test |
Completed |
: 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) : Autosomal Dominant Polycystic Kidney Disease : 2011-10-11 :
|
Recruiting |
: A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease : Autosomal Dominant Polycystic Kidney : 2017-03-27 : Other: High Water Intake After 6 months of usual, unchanged diet and fluid intake, participants will be |
Completed |
: Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) : Autosomal Dominant Polycystic Kidney Disease (ADPKD) : 2006-06-22 :
|
Completed |
: Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) : Autosomal Dominant Polycystic Kidney Disease : 2008-09-24 : Other: Water prescription Water prescription in 12 to 16 equally divided doses |
Completed |
: Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease : Autosomal Dominant Polycystic Kidney Disease : 2006-12-20 :
|
Completed |
: A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001] : Autosomal Dominant Polycystic Kidney Disease : 2009-02-09 : Drug: OPC-41061 orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years. |
Terminated |
: Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency : Autosomal Dominant Polycystic Kidney Disease (ADPKD) : 2010-10-12 :
|
Completed |
: A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002] : Autosomal Dominant Polycystic Kidney Disease : 2009-11-27 : Drug: OPC-41061 Repeated oral administration at doses of 15 mg twice daily (morning and evening) |
Not yet recruiting |
: The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain : Autosomal Dominant Polycystic Kidney Disease : 2016-04-08 : Device: Vessix Renal denervation using radio-ablation |